Amgen Inc.
SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND

Last updated:

Abstract:

The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure ##STR00001## useful for the synthesis of compounds that target KRAS G12C mutations, such as ##STR00002##

Status:
Application
Type:

Utility

Filling date:

8 Mar 2022

Issue date:

14 Jul 2022